Google
DHR Stock Analysis — DANAHER CORPORATION (Healthcare >> Diagnostics & Research)
DHR FAQ
What is DHR's P/E ratio?
DANAHER CORPORATION (DHR) currently trades at a P/E ratio of 34.44.
What is DHR's ROE?
DANAHER CORPORATION reports a Return on Equity (ROE) of 7.61%.
What is DHR's dividend yield?
DANAHER CORPORATION offers a dividend yield of 0.73%.
What is DHR's Quality Score?
Our AI rates DHR's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy DHR?
Our AI Timing Score for DHR is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does DHR belong to?
DANAHER CORPORATION is classified under the Healthcare >> Diagnostics & Research sector on the NYSE exchange
DHR AI Analysis Summary
Our AI summary for DHR: DANAHER CORPORATION (NYSE), Healthcare >> Diagnostics & Research sector. The stock currently trades at a P/E of 34.44, ROE of 7.61%, a dividend yield of 0.73%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 194.98
Price
-1.19
(-0.61%)
Day Change
|
|
|---|
DHR, the overall quality is not quite good ( Quality = 54) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...
| Quality Factors |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
2239
|
| Magic Formula Rank by ROE |
2239
|
| Magic Formula Rank by ROIC |
2595
|
| Price | 194.98 |
| PBV / Sector |
2.62 / -29.69
|
| Earning Per Share | 5.66 |
| PE / Sector |
34.44 / 48.18
|
| PEG or PE/Growth / Sector |
-1.85 / 1.64
|
| Average 1M Daily Value |
1,161.39 M
GREAT
|
| Average 1W Daily Value |
1,099.64 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
54% |
| Ability to Make Profit |
|
64% |
| Return to Investors |
|
41% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:43 |
| Symbol | DHR |
| Name | DANAHER CORPORATION |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NYSE |
| Listed Shares | 702.99 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 137,904.77 / 38,081.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2200 Pennsylvania Avenue N.W., Washington, DC, United States, 20037-1701
Phone: 202 828 0850
Website: https://www.danaher.com
Employees: 58,000
Description: Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
